Xiaoling Guan

Xiaoling Guan

Auto-generated profile, based on publicly available information

Xiaoling Guan

Department of Endocrinology and Metabology

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Environmental Science & Technology
Verified
Journal Article
Closed access
MLMei Liu
Mei Liu
ALAn Li
An Li
LMLingling Meng
Lingling Meng
GZGaoxin Zhang
Gaoxin Zhang
XGXiaoling Guan
Xiaoling Guan
GJGuibin Jiang
Guibin Jiang

29 October 2022 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
JGJiemei Gu
Jiemei Gu
HZHao Zhang
Hao Zhang
QXQingyun Xue
Qingyun Xue
LWLi Wang
Li Wang
ZCZhifeng Cheng
Zhifeng Cheng
ZZZhenlin Zhang
Zhenlin Zhang
This study assessed the efficacy, safety, pharmacokinetics (PK), and immunogenicity profiles of a denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women with a high risk of fracture. In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, 448 postmenopausal women aged 50–85 years with osteoporosis were enrolled at 49 centers in China and were randomly assigned (3:1) to receive 60 ​mg of the denosumab biosimilar (LY06006) or placebo subcutaneously every 6 months for 1 year. Lumbar spine bone mineral density (BMD) change was the primary endpoint. Of the 448 randomized patients, 409 (LY06006, n ​= ​311; placebo, n ​= ​98) completed the study. All 448 (100.0%) subjects were included in the intent-to-treat (ITT) trial, 427 (95.3%) were included in the full analysis set (FAS), 408 (91.1%) were included in the per protocol set (PPS), 446 (99.6%) were included in the safety set (SS), and 336 (75.0%) were included in the pharmacokinetics concentration set (PKCs). For the primary endpoint, a 4.71% (95% CI, 3.81%, 5.60%) treatment difference in percent change in lumbar spine BMD from baseline to month 12 was observed in the LY06006 group compared with the placebo group (P ​< ​0.0001). For the secondary endpoints, LY06006 was associated with increased lumbar spine BMD levels measured at month 6, BMD levels at the femoral neck, total hip, and trochanter measured at months 6 and 12 and reduced serum C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 ​N-peptide (P1NP) levels at months 1, 6, and 12. Safety analysis was based on the safety analysis set (SS), and 264 (78.6%) subjects in the LY06006 group and 83 (75.5%) in the placebo group experienced adverse events (AEs). Most events were mild or moderate and not related to the study drugs. In postmenopausal women with a high risk of fracture, LY06006 increased the BMD and decreased bone resorption; thus, LY06006 might be an effective treatment for osteoporosis. LY06006 was generally safe and well tolerated without unexpected adverse reactions, similar to the reference drug Prolia®. The characteristics of effectiveness and safety were similar to those reported in previous studies. In this multi-center, randomized, double-blind, placebo-controlled phase 3 study, LY06006 showed substantially efficacy to increase BMD and well tolerance without unexpected adverse reactions, which is comparable to the reference drug Prolia ®. The presented results are encouraging and can offer some valuable evidence for the clinical practice.

21 August 2015 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
ZZZhongwen Zhang
Zhongwen Zhang
XZXiaoqian Zhang
Xiaoqian Zhang
JDJianjun Dong
Jianjun Dong
WGWeiyi Gao
Weiyi Gao
FLFupeng Liu
Fupeng Liu
LLLin Liao
Lin Liao
Chemokine ligand 5 (CCL5) is a member of the CC-chemokine family expressed in various organs. It contributes to the migration of monocytes/macrophages into injured vascular walls by binding with its receptor chemokine receptor 5 (CCR5). Many studies have accessed the association between CCL5/CCR5 gene promoter polymorphisms and diabetic microvascular complications (DMI). However, the results are conflicting and inconclusive. The aim of the present study was to evaluate the association more precisely. Trials were retrieved through PubMed, Embase, Medline, China National Knowledge Infrastructure, Web of Science and Cochrane database without restrictions on language. The pooled odds ratio (OR) and 95% confidence interval (CI) were used to describe the strength of association with DMI. Data were obtained from 11 case-control studies that included 2,737 DMI patients and 2,435 diabetic control subjects. In the overall analysis, the CCL5-403 G/A and CCL5-28 C/G gene polymorphisms were not significantly associated with the risk of DMI. However, CCR5-59029 G/A was an independent risk factor of DMI in a dominant model (OR 1.77, 95% CI 1.06-2.97). Subgroup analysis showed that the risk of the CCR5 59029A-positive genotype was significant in Asians (OR 2.08, 95% CI 1.68-2.57). In addition, the CCR5 59029A-positive genotype was associated with increased risk of albuminuria. There were no associations of CCL5 gene promoter polymorphism with the risk of DMI. However, the 59029A polymorphism in CCR5 might affect individual susceptibility for DMI.

4 March 2019 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
LLLu Liu
Lu Liu
XGXiaoling Guan
Xiaoling Guan
ZYZhongshang Yuan
Zhongshang Yuan
MZMeng Zhao
Meng Zhao
QLQiu Li
Qiu Li
TGthe REACTION Study Group
the REACTION Study Group
Aim. It is known that different stages of type 2 diabetes represent distinct pathophysiological changes, but how the spectrum of risk factors varies at different stages is not yet clarified. Hence, the aim of this study was to compare the effect of different metabolic variables on the natural history of type 2 diabetes. Methods. A total of 5,213 nondiabetic (normal glucose tolerance (NGT) and prediabetes) Chinese older than 40 years participated this prospective cohort study, and 4,577 completed the 3-year follow-up. Glycemic status was determined by standard oral glucose tolerance test both at enrollment and follow-up visit. Predictors for conversion in glycemic status were studied in a corresponding subcohort using the multiple logistic regression analysis. Results. The incidence of prediabetes and diabetes of the cohort was 93.6 and 42.2 per 1,000 person-years, respectively. After a 3-year follow-up, 33.1% of prediabetes patients regressed to NGT. The predictive weight of body mass index (BMI), serum triglyceride, total cholesterol, and systolic blood pressure in different paths of conversions among diabetes, prediabetes, and NGT differed. Specifically, BMI was the strongest predictor for regression from prediabetes to NGT, while triglyceride was most prominent for onset of diabetes. One SD increase in serum triglyceride was associated with a 1.29- (95% CI 1.10–1.52; P=0.002) or 1.12- (95% CI 1.01–1.27; P=0.039) fold higher risk of diabetes for individuals with NGT or prediabetes, respectively. Conclusion. Risk factors for different stages of diabetes differed, suggesting personalized preventive strategies for individuals with different basal glycemic statuses.

1 January 2014
Verified
Journal Article
Open access
XGXiaoling Guan
Xiaoling Guan
HYHuajie Yang
Huajie Yang
WZWei Zhang
Wei Zhang
HWHuanjun Wang
Huanjun Wang
LLLin Liao
Lin Liao
To review the advances of studies on vitamin D receptor and its role in the pathogenesis of diabetic nephropathy. A comprehensive search of the PubMed literatures without restriction on the publication date was carried out using keywords such as vitamin D receptor and diabetic nephropathy. Articles related to vitamin D receptor and diabetic nephropathy were selected and carefully analyzed. The ligands as well as construction and tissue distribution of vitamin D receptor were summarized. Pathogenesis of diabetic nephropathy was analyzed. The mechanisms underlying the renoprotective role of vitamin D receptor including inhibition of renin-angiotensin system, anti-inflammation, anti-fibrosis and the reduction of proteinuria were reviewed. Mounting evidences from animal and clinical studies have suggested that vitamin D therapy has beneficial effects on the renal systems and the underlying renoprotective mechanisms of the vitamin D receptor-mediated signaling pathways is a hot research topic. Our study suggests that vitamin D receptor has a great potential for preventing the progression of diabetic nephropathy via multiple mechanisms.

2 May 2025 in Environment & Health
Verified
Journal Article
Open access
MLMei Liu
Mei Liu
XGXiaoling Guan
Xiaoling Guan
LMLingling Meng
Lingling Meng
GZGaoxin Zhang
Gaoxin Zhang
JLJiyan Liu
Jiyan Liu
GJGuibin Jiang
Guibin Jiang
Exposure to short-chain polychlorinated alkanes (PCAs-C10–13) can disturb thyroid homeostasis, warranting an in-depth analysis of their relationship with thyroid risk and related clinical parameters. This study recruited and obtained serum samples from 478 participants in Shandong, China, including 240 thyroid cancer patients and 238 healthy controls. PCAs-C10 presented as the predominant homologues in both case and control groups. PCAs-C10–13 exposure displayed an essential role in thyroid cancer risk, in which a nonlinear dose-risk relationship was observed for PCAs-C10–13, with PCAs-C12 and PCAs-C13 exhibiting significantly reduced risks (odds ratios < 1) for thyroid cancer. Specific PCAs-C10–13 homologues were significantly associated with triglycerides, cholesterol, low-density lipoprotein cholesterol, and total lipid in the control group. Weighted quantile sum regression and Bayesian kernel machine regression revealed predominantly negative combined effects of PCAs-C10–13 exposure on thyroid cancer, thyroid hormone, and serum lipid parameters. Our results showed that exposure to the current environmental level of PCAs-C10–13 cannot heighten risks of thyroid cancer. Overall, this study first provides epidemiological evidence on the potential implications of PCAs-C10–13 exposure and thyroid cancer risk.